[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fnuloNrT0zBlrtdpA3t-7nK-pJPXeoa6_nCwclFS_93s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":46,"rows":53},"Puma Biotechnology, Inc.",[4],38,false,3,2,8565,1,[13,16,19,22,24,26,28,30],{"name":14,"count":15},"Healthy",8,{"name":17,"count":18},"Breast Cancer",7,{"name":20,"count":21},"Advanced Malignant Solid Tumors",5,{"name":23,"count":8},"Breast Neoplasms",{"name":25,"count":8},"Advanced Breast Cancer",{"name":27,"count":8},"Healthy Subjects",{"name":29,"count":9},"Neoplasms",{"name":31,"count":11},"HER2 Amplified Breast Cancer",[33,38,42],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06095505","A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","2027-04-30","Alisertib",{"nctId":39,"briefTitle":40,"date":41,"intervention":37},"NCT06369285","A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","2027-06-30",{"nctId":43,"briefTitle":44,"date":45,"intervention":37},"NCT07465757","A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","2028-03-31",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,99,162,180,247,269,315,355,381,411,444,462,480,498,522,546,568],{"intervention":37,"totalTrials":8,"cells":55},{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":93,"PHASE4":95,"NA":97},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":8,"soonestReadout":36},[63,72,82],{"nctId":34,"briefTitle":35,"status":64,"phases":65,"primaryCompletion":36,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":71},"RECRUITING",[49],"2027-10-31","2024-02-08",80,[70],"Small Cell Lung Cancer",[37],{"nctId":43,"briefTitle":44,"status":73,"phases":74,"primaryCompletion":45,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":80},"NOT_YET_RECRUITING",[49],"2028-09-30","2026-09-30",50,[79],"Small Cell Lung Cancer ( SCLC )",[37,37,37,37,37,81],"Paclitaxel",{"nctId":39,"briefTitle":40,"status":64,"phases":83,"primaryCompletion":41,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":91},[49],"2028-12-31","2024-11-19",150,[88,89,90],"Hormone Receptor Positive HER-2 Negative Breast Cancer","Metastatic Breast Cancer","Recurrent Breast Cancer",[37,92],"Endocrine therapy",{"trials":94,"activeCount":58},[],{"trials":96,"activeCount":58},[],{"trials":98,"activeCount":58},[],{"intervention":81,"totalTrials":21,"cells":100},{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":116,"PHASE3":156,"PHASE4":158,"NA":160},{"trials":102,"activeCount":58},[],{"trials":104,"activeCount":58},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"NCT00768469","Study Evaluating Safety And Tolerability, Solid Tumor","COMPLETED",[48],"2011-01","2008-10",10,[20],[115,81],"Neratinib",{"trials":117,"activeCount":11,"soonestReadout":45},[118,129,140,144],{"nctId":119,"briefTitle":120,"status":108,"phases":121,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":127},"NCT00915018","Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer",[49],"2013-08","2018-06-28","2009-08-21",479,[17],[115,128,81],"Trastuzumab",{"nctId":130,"briefTitle":131,"status":108,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT00445458","A Phase 1\u002F2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer",[48,49],"2011-05","2018-02-07","2007-09-11",110,[25,20,23],[139,81],"HKI-272",{"nctId":43,"briefTitle":44,"status":73,"phases":141,"primaryCompletion":45,"completion":75,"start":76,"enrollment":77,"conditions":142,"interventions":143},[49],[79],[37,37,37,37,37,81],{"nctId":145,"briefTitle":146,"status":147,"phases":148,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":154},"NCT01953926","Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","TERMINATED",[49],"2023-01-02","2013-09-30",582,[153],"Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations",[115,155,128,81],"Fulvestrant",{"trials":157,"activeCount":58},[],{"trials":159,"activeCount":58},[],{"trials":161,"activeCount":58},[],{"intervention":92,"totalTrials":11,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":174,"PHASE4":176,"NA":178},{"trials":165,"activeCount":58},[],{"trials":167,"activeCount":58},[],{"trials":169,"activeCount":11,"soonestReadout":41},[170],{"nctId":39,"briefTitle":40,"status":64,"phases":171,"primaryCompletion":41,"completion":84,"start":85,"enrollment":86,"conditions":172,"interventions":173},[49],[88,89,90],[37,92],{"trials":175,"activeCount":58},[],{"trials":177,"activeCount":58},[],{"trials":179,"activeCount":58},[],{"intervention":181,"totalTrials":21,"cells":182},"Capecitabine",{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":195,"PHASE3":227,"PHASE4":243,"NA":245},{"trials":184,"activeCount":58},[],{"trials":186,"activeCount":58},[187],{"nctId":188,"briefTitle":189,"status":108,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":18,"conditions":193,"interventions":194},"NCT01128842","A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor",[48],"2011-03","2010-04",[20],[115,181],{"trials":196,"activeCount":58},[197,207,217],{"nctId":198,"briefTitle":199,"status":108,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":205},"NCT04366713","A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib",[49],"2021-12-28","2020-06-30",6,[31],[115,181,206],"Loperamide",{"nctId":208,"briefTitle":209,"status":108,"phases":210,"primaryCompletion":191,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":215},"NCT00777101","Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer",[49],"2018-06-03","2009-02-04",233,[25,17],[115,216,181],"Lapatinib",{"nctId":218,"briefTitle":219,"status":108,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":226},"NCT00741260","Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer",[48,49],"2010-11","2018-06","2008-12-09",105,[17],[115,181],{"trials":228,"activeCount":58},[229],{"nctId":230,"briefTitle":231,"status":108,"phases":232,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":239},"NCT01808573","A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting",[50],"2018-09-28","2019-12-09","2013-03-29",621,[238],"HER2+ Metastatic Breast Cancer (MBC)",[240,241,242],"neratinib","capecitabine","lapatinib",{"trials":244,"activeCount":58},[],{"trials":246,"activeCount":58},[],{"intervention":216,"totalTrials":9,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":259,"PHASE4":265,"NA":267},{"trials":250,"activeCount":58},[],{"trials":252,"activeCount":58},[],{"trials":254,"activeCount":58},[255],{"nctId":208,"briefTitle":209,"status":108,"phases":256,"primaryCompletion":191,"completion":211,"start":212,"enrollment":213,"conditions":257,"interventions":258},[49],[25,17],[115,216,181],{"trials":260,"activeCount":58},[261],{"nctId":230,"briefTitle":231,"status":108,"phases":262,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":263,"interventions":264},[50],[238],[240,241,242],{"trials":266,"activeCount":58},[],{"trials":268,"activeCount":58},[],{"intervention":270,"totalTrials":8,"cells":271},"Temsirolimus",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":287,"PHASE3":309,"PHASE4":311,"NA":313},{"trials":273,"activeCount":58},[],{"trials":275,"activeCount":58},[276],{"nctId":277,"briefTitle":278,"status":108,"phases":279,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":286},"NCT00838539","Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors",[48],"2011-06","2013-12","2009-04",63,[29,285],"Malignant Carcinoma",[115,270],{"trials":288,"activeCount":58},[289,297],{"nctId":290,"briefTitle":291,"status":108,"phases":292,"primaryCompletion":293,"completion":293,"start":192,"enrollment":294,"conditions":295,"interventions":296},"NCT01111825","Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer",[48,49],"2016-07",99,[17],[270,115],{"nctId":298,"briefTitle":299,"status":108,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT01827267","Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer",[49],"2016-09-20","2017-10-06","2013-07-01",62,[306],"HER2-mutant Non-Small Cell Lung Cancer",[240,308],"temsirolimus",{"trials":310,"activeCount":58},[],{"trials":312,"activeCount":58},[],{"trials":314,"activeCount":58},[],{"intervention":139,"totalTrials":8,"cells":316},{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":318,"activeCount":58},[],{"trials":320,"activeCount":58},[],{"trials":322,"activeCount":58},[323,334,338],{"nctId":324,"briefTitle":325,"status":108,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":332},"NCT00398567","A Phase 1\u002F2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer",[48,49],"2009-07-31","2018-03-02","2007-04-04",45,[25],[139,333],"trastuzumab",{"nctId":130,"briefTitle":131,"status":108,"phases":335,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":336,"interventions":337},[48,49],[25,20,23],[139,81],{"nctId":339,"briefTitle":340,"status":108,"phases":341,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":348},"NCT00266877","Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer",[49],"2009-01","2005-12",172,[346,347],"Carcinoma, Non-Small-Cell Lung","Lung Neoplasms",[139],{"trials":350,"activeCount":58},[],{"trials":352,"activeCount":58},[],{"trials":354,"activeCount":58},[],{"intervention":128,"totalTrials":8,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":358,"activeCount":58},[],{"trials":360,"activeCount":58},[],{"trials":362,"activeCount":58},[363,367,371],{"nctId":324,"briefTitle":325,"status":108,"phases":364,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":365,"interventions":366},[48,49],[25],[139,333],{"nctId":119,"briefTitle":120,"status":108,"phases":368,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":369,"interventions":370},[49],[17],[115,128,81],{"nctId":145,"briefTitle":146,"status":147,"phases":372,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":373,"interventions":374},[49],[153],[115,155,128,81],{"trials":376,"activeCount":58},[],{"trials":378,"activeCount":58},[],{"trials":380,"activeCount":58},[],{"intervention":206,"totalTrials":9,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":405,"PHASE4":407,"NA":409},{"trials":384,"activeCount":58},[],{"trials":386,"activeCount":58},[],{"trials":388,"activeCount":58},[389,393],{"nctId":198,"briefTitle":199,"status":108,"phases":390,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":391,"interventions":392},[49],[31],[115,181,206],{"nctId":394,"briefTitle":395,"status":108,"phases":396,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":402},"NCT02400476","An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide",[49],"2021-04-22","2015-02",563,[401],"Early Stage HER2+ Breast Cancer",[115,206,403,404],"Colestipol","Budesonide",{"trials":406,"activeCount":58},[],{"trials":408,"activeCount":58},[],{"trials":410,"activeCount":58},[],{"intervention":412,"totalTrials":9,"cells":413},"vinorelbine",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":426,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":415,"activeCount":58},[],{"trials":417,"activeCount":58},[418],{"nctId":419,"briefTitle":420,"status":108,"phases":421,"primaryCompletion":192,"completion":192,"start":422,"enrollment":203,"conditions":423,"interventions":424},"NCT00958724","Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors",[48],"2009-07",[20],[115,425],"Vinorelbine",{"trials":427,"activeCount":58},[428],{"nctId":429,"briefTitle":430,"status":108,"phases":431,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":437},"NCT00706030","Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer",[48,49],"2009-10","2018-06-07","2008-04-29",92,[17,20],[240,412],{"trials":439,"activeCount":58},[],{"trials":441,"activeCount":58},[],{"trials":443,"activeCount":58},[],{"intervention":155,"totalTrials":11,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":447,"activeCount":58},[],{"trials":449,"activeCount":58},[],{"trials":451,"activeCount":58},[452],{"nctId":145,"briefTitle":146,"status":147,"phases":453,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":454,"interventions":455},[49],[153],[115,155,128,81],{"trials":457,"activeCount":58},[],{"trials":459,"activeCount":58},[],{"trials":461,"activeCount":58},[],{"intervention":403,"totalTrials":11,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":474,"PHASE4":476,"NA":478},{"trials":465,"activeCount":58},[],{"trials":467,"activeCount":58},[],{"trials":469,"activeCount":58},[470],{"nctId":394,"briefTitle":395,"status":108,"phases":471,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":472,"interventions":473},[49],[401],[115,206,403,404],{"trials":475,"activeCount":58},[],{"trials":477,"activeCount":58},[],{"trials":479,"activeCount":58},[],{"intervention":404,"totalTrials":11,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":492,"PHASE4":494,"NA":496},{"trials":483,"activeCount":58},[],{"trials":485,"activeCount":58},[],{"trials":487,"activeCount":58},[488],{"nctId":394,"briefTitle":395,"status":108,"phases":489,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":490,"interventions":491},[49],[401],[115,206,403,404],{"trials":493,"activeCount":58},[],{"trials":495,"activeCount":58},[],{"trials":497,"activeCount":58},[],{"intervention":499,"totalTrials":11,"cells":500},"Moxifloxacin",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":502,"activeCount":58},[],{"trials":504,"activeCount":58},[505],{"nctId":506,"briefTitle":507,"status":108,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":513},"NCT00708903","Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)",[48],"2008-07","2008-05",60,[17],[240,499],{"trials":515,"activeCount":58},[],{"trials":517,"activeCount":58},[],{"trials":519,"activeCount":58},[],{"trials":521,"activeCount":58},[],{"intervention":523,"totalTrials":11,"cells":524},"Lansoprazole",{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":544},{"trials":526,"activeCount":58},[],{"trials":528,"activeCount":58},[529],{"nctId":530,"briefTitle":531,"status":108,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":537},"NCT02334501","Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects",[48],"2014-10","2014-08",15,[14],[523,115],{"trials":539,"activeCount":58},[],{"trials":541,"activeCount":58},[],{"trials":543,"activeCount":58},[],{"trials":545,"activeCount":58},[],{"intervention":547,"totalTrials":11,"cells":548},"Digoxin",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":560,"PHASE3":562,"PHASE4":564,"NA":566},{"trials":550,"activeCount":58},[],{"trials":552,"activeCount":58},[553],{"nctId":554,"briefTitle":555,"status":108,"phases":556,"primaryCompletion":282,"completion":282,"start":282,"enrollment":557,"conditions":558,"interventions":559},"NCT00860223","Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin",[48],27,[14],[547,115],{"trials":561,"activeCount":58},[],{"trials":563,"activeCount":58},[],{"trials":565,"activeCount":58},[],{"trials":567,"activeCount":58},[],{"intervention":115,"totalTrials":569,"cells":570},31,{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":691,"PHASE3":738,"PHASE4":754,"NA":756},{"trials":572,"activeCount":58},[],{"trials":574,"activeCount":58},[575,584,588,592,601,605,614,623,627,631,637,641,648,656,660,668,677,683],{"nctId":576,"briefTitle":577,"status":108,"phases":578,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":583},"NCT00146172","Study Evaluating HKI-272 in Tumors",[48],"2007-01","2003-11",73,[23],[240],{"nctId":506,"briefTitle":507,"status":108,"phases":585,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":586,"interventions":587},[48],[17],[240,499],{"nctId":530,"briefTitle":531,"status":108,"phases":589,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":590,"interventions":591},[48],[14],[523,115],{"nctId":593,"briefTitle":594,"status":108,"phases":595,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":600},"NCT00380328","HKI-272 Ketoconazole Drug Interaction Study",[48],"2006-11","2006-10",24,[14],[240],{"nctId":554,"briefTitle":555,"status":108,"phases":602,"primaryCompletion":282,"completion":282,"start":282,"enrollment":557,"conditions":603,"interventions":604},[48],[14],[547,115],{"nctId":606,"briefTitle":607,"status":108,"phases":608,"primaryCompletion":609,"completion":609,"start":596,"enrollment":610,"conditions":611,"interventions":613},"NCT00397046","A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors",[48],"2009-03",21,[612],"Tumors",[240],{"nctId":615,"briefTitle":616,"status":108,"phases":617,"primaryCompletion":618,"completion":618,"start":619,"enrollment":620,"conditions":621,"interventions":622},"NCT00366600","Study Evaluating HKI-272 Administered to Healthy Subjects",[48],"2006-12","2006-07",56,[14],[240],{"nctId":419,"briefTitle":420,"status":108,"phases":624,"primaryCompletion":192,"completion":192,"start":422,"enrollment":203,"conditions":625,"interventions":626},[48],[20],[115,425],{"nctId":188,"briefTitle":189,"status":108,"phases":628,"primaryCompletion":191,"completion":191,"start":192,"enrollment":18,"conditions":629,"interventions":630},[48],[20],[115,181],{"nctId":632,"briefTitle":633,"status":108,"phases":634,"primaryCompletion":609,"completion":609,"start":342,"enrollment":598,"conditions":635,"interventions":636},"NCT00814060","Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)",[48],[27],[240],{"nctId":277,"briefTitle":278,"status":108,"phases":638,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":639,"interventions":640},[48],[29,285],[115,270],{"nctId":642,"briefTitle":643,"status":108,"phases":644,"primaryCompletion":645,"completion":645,"start":282,"enrollment":598,"conditions":646,"interventions":647},"NCT00864487","Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib",[48],"2009-05",[27],[115],{"nctId":649,"briefTitle":650,"status":108,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":203,"conditions":654,"interventions":655},"NCT00550212","Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects",[48],"2008-04","2008-03",[14],[240],{"nctId":106,"briefTitle":107,"status":108,"phases":657,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":658,"interventions":659},[48],[20],[115,81],{"nctId":661,"briefTitle":662,"status":663,"phases":664,"primaryCompletion":665,"completion":665,"start":665,"enrollment":58,"conditions":666,"interventions":667},"NCT00932464","Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib","WITHDRAWN",[48],"2012-08",[14],[115,115],{"nctId":669,"briefTitle":670,"status":108,"phases":671,"completion":672,"start":673,"enrollment":674,"conditions":675,"interventions":676},"NCT00498745","Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects",[48],"2007-09","2007-07",36,[14],[240],{"nctId":678,"briefTitle":679,"status":108,"phases":680,"primaryCompletion":111,"completion":111,"start":111,"enrollment":77,"conditions":681,"interventions":682},"NCT00757809","Study Evaluating The Tolerability Of Multiple Doses Of HKI-272",[48],[27],[240],{"nctId":684,"briefTitle":685,"status":108,"phases":686,"primaryCompletion":687,"completion":687,"start":282,"enrollment":557,"conditions":688,"interventions":690},"NCT00781430","Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease",[48],"2010-02",[689],"Hepatic Insufficiency",[115],{"trials":692,"activeCount":58},[693,697,701,705,709,718,722,726,730,734],{"nctId":290,"briefTitle":291,"status":108,"phases":694,"primaryCompletion":293,"completion":293,"start":192,"enrollment":294,"conditions":695,"interventions":696},[48,49],[17],[270,115],{"nctId":198,"briefTitle":199,"status":108,"phases":698,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":699,"interventions":700},[49],[31],[115,181,206],{"nctId":298,"briefTitle":299,"status":108,"phases":702,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":703,"interventions":704},[49],[306],[240,308],{"nctId":208,"briefTitle":209,"status":108,"phases":706,"primaryCompletion":191,"completion":211,"start":212,"enrollment":213,"conditions":707,"interventions":708},[49],[25,17],[115,216,181],{"nctId":710,"briefTitle":711,"status":108,"phases":712,"primaryCompletion":652,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":717},"NCT00300781","Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer",[49],"2018-01-30","2006-08-04",136,[23,29],[240],{"nctId":119,"briefTitle":120,"status":108,"phases":719,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":720,"interventions":721},[49],[17],[115,128,81],{"nctId":429,"briefTitle":430,"status":108,"phases":723,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":724,"interventions":725},[48,49],[17,20],[240,412],{"nctId":218,"briefTitle":219,"status":108,"phases":727,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":728,"interventions":729},[48,49],[17],[115,181],{"nctId":145,"briefTitle":146,"status":147,"phases":731,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":732,"interventions":733},[49],[153],[115,155,128,81],{"nctId":394,"briefTitle":395,"status":108,"phases":735,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":736,"interventions":737},[49],[401],[115,206,403,404],{"trials":739,"activeCount":58},[740,744],{"nctId":230,"briefTitle":231,"status":108,"phases":741,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":742,"interventions":743},[50],[238],[240,241,242],{"nctId":745,"briefTitle":746,"status":108,"phases":747,"primaryCompletion":748,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":753},"NCT00878709","Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer",[50],"2014-08-21","2019-10-04","2009-07-09",2840,[17],[240],{"trials":755,"activeCount":58},[],{"trials":757,"activeCount":58},[758],{"nctId":759,"briefTitle":760,"status":108,"phases":761,"primaryCompletion":762,"completion":762,"start":763,"enrollment":764,"conditions":765,"interventions":766},"NCT01142063","A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects",[],"2010-09","2010-06",28,[14],[115,115,115,115]]